Organon & Co.
OGN · Pharmaceutical Preparations · 262.6M shares · +0%/yr ↑ shares · EDGAR filings ↗
Reference price $13.35 · est. market cap ~$3.5B — last insider sale, 2026-05-06 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C68Profitable, cash-generative women's-health pharma with high but leverage-inflated ROE, offset by thin margins, heavy debt and governance turmoil.
Strengths
- Strong returns and cash: ROE 24.9% (83rd pct), ROA 1.5% (86th), FCF $538M (95th), FCF margin 8.7% (76th)
- Diversified 70+ product portfolio with Nexplanon franchise (extended to 5-year use) and durable established brands
Risks
- Extreme leverage (D/E 11.5, 99th pct) inflating ROE; thin net margin (3%), weak liquidity and a $301M goodwill impairment
- Governance red flag: CEO resigned Oct 2025 amid an audit-committee investigation; ongoing LOE erosion (Atozet, coming Nexplanon patent cliffs)
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- High leverageHigh leverage (debt/equity 11.49)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$353,080, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-10 — PHASE3 · Plaque Psoriasis
- Insider sellingInsider selling — 1 open-market sale(s) by 1 insider(s) (~$353,080, last 6mo) Form 4 ↗
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, FMR LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
53.3%
Net margin
3.0%
Return on equity
24.9%
Return on assets
1.5%
Revenue growth (QoQ)
-3.1%
Net-income growth
-78.4%
Debt / equity
11.5×
Current ratio
1.8×
Free cash flow
$538M
Tangible book value
-$4.5B
Cash & investments
$574M
Stock comp / revenue
1.2%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-06 | Holzbaur Lynette | Other | 46 | — |
| 2026-05-06 | Holzbaur Lynette | Buy | 26K | $13.35 |
| 2026-05-06 | Holzbaur Lynette | Sell | 26K | $13.35 |
| 2026-03-31 | Drinane Juliana Papa | Option exercise | 10K | — |
| 2026-03-31 | Drinane Juliana Papa | Tax withheld | 3.5K | $5.70 |
| 2026-03-31 | Arjona Ferreira Juan Camilo | Option exercise | 13K | — |
| 2026-03-31 | Arjona Ferreira Juan Camilo | Tax withheld | 4.8K | $5.70 |
| 2026-03-31 | Karp Daniel | Option exercise | 11K | — |
| 2026-03-31 | Karp Daniel | Tax withheld | 3.6K | $5.70 |
| 2026-03-31 | Karp Daniel | Option exercise | 6.7K | — |
| 2026-03-31 | Karp Daniel | Tax withheld | 2.1K | $5.70 |
| 2026-03-31 | Stahler Rachel A | Option exercise | 6.6K | — |
| 2026-03-31 | Stahler Rachel A | Tax withheld | 2.2K | $5.70 |
| 2026-03-31 | Stahler Rachel A | Option exercise | 12K | — |
| 2026-03-31 | Stahler Rachel A | Tax withheld | 4.2K | $5.70 |
| 2026-03-31 | WALSH MATTHEW M | Option exercise | 12K | — |
| 2026-03-31 | WALSH MATTHEW M | Tax withheld | 4.1K | $5.70 |
| 2026-03-31 | WALSH MATTHEW M | Option exercise | 22K | — |
| 2026-03-31 | WALSH MATTHEW M | Tax withheld | 7.4K | $5.70 |
| 2026-03-31 | Falcione Aaron | Option exercise | 6.7K | — |
| 2026-03-31 | Falcione Aaron | Tax withheld | 2.3K | $5.70 |
| 2026-03-31 | Falcione Aaron | Option exercise | 11K | — |
| 2026-03-31 | Falcione Aaron | Tax withheld | 3.8K | $5.70 |
| 2026-03-31 | Weaver Kirke | Option exercise | 6.2K | — |
| 2026-03-31 | Weaver Kirke | Tax withheld | 1.8K | $5.70 |
| 2026-03-31 | Weaver Kirke | Option exercise | 12K | — |
| 2026-03-31 | Weaver Kirke | Tax withheld | 3.5K | $5.70 |
| 2026-03-31 | Nisita Vittorio | Option exercise | 4.6K | — |
| 2026-03-31 | Nisita Vittorio | Tax withheld | 1.6K | $5.70 |
| 2026-03-31 | Nisita Vittorio | Option exercise | 8.4K | — |
| 2026-03-31 | Nisita Vittorio | Tax withheld | 2.9K | $5.70 |
| 2026-03-31 | Holzbaur Lynette | Option exercise | 4.3K | — |
| 2026-03-31 | Holzbaur Lynette | Tax withheld | 1.2K | $5.70 |
| 2026-03-31 | Holzbaur Lynette | Option exercise | 6.7K | — |
| 2026-03-31 | Holzbaur Lynette | Tax withheld | 1.9K | $5.70 |
| 2026-03-31 | Morrissey Joseph T. Jr. | Option exercise | 7.8K | — |
| 2026-03-31 | Morrissey Joseph T. Jr. | Tax withheld | 2.2K | $5.70 |
| 2026-03-31 | Morrissey Joseph T. Jr. | Option exercise | 17K | — |
| 2026-03-31 | Morrissey Joseph T. Jr. | Tax withheld | 4.8K | $5.70 |
| 2026-03-31 | Drinane Juliana Papa | Option exercise | 6.4K | — |
| 2026-03-31 | Drinane Juliana Papa | Tax withheld | 2.2K | $5.70 |
| 2026-03-29 | WALSH MATTHEW M | Option exercise | 15K | — |
| 2026-03-29 | Stahler Rachel A | Option exercise | 8.2K | — |
| 2026-03-29 | Stahler Rachel A | Tax withheld | 2.8K | $5.84 |
| 2026-03-29 | Holzbaur Lynette | Option exercise | 5.3K | — |
| 2026-03-29 | Holzbaur Lynette | Tax withheld | 1.5K | $5.84 |
| 2026-03-29 | Karp Daniel | Option exercise | 14K | — |
| 2026-03-29 | Karp Daniel | Tax withheld | 4.4K | $5.84 |
| 2026-03-29 | Weaver Kirke | Option exercise | 7.8K | — |
| 2026-03-29 | Weaver Kirke | Tax withheld | 2.2K | $5.84 |
| 2026-03-29 | Nisita Vittorio | Option exercise | 5.8K | — |
| 2026-03-29 | Nisita Vittorio | Tax withheld | 2.0K | $5.84 |
| 2026-03-29 | Drinane Juliana Papa | Option exercise | 8.0K | — |
| 2026-03-29 | Drinane Juliana Papa | Tax withheld | 2.7K | $5.84 |
| 2026-03-29 | Arjona Ferreira Juan Camilo | Option exercise | 8.9K | — |
| 2026-03-29 | Arjona Ferreira Juan Camilo | Tax withheld | 3.2K | $5.84 |
| 2026-03-29 | Falcione Aaron | Option exercise | 8.4K | — |
| 2026-03-29 | Falcione Aaron | Tax withheld | 2.9K | $5.84 |
| 2026-03-29 | WALSH MATTHEW M | Tax withheld | 5.2K | $5.84 |
| 2026-03-29 | Morrissey Joseph T. Jr. | Option exercise | 9.8K | — |
| 2026-03-29 | Morrissey Joseph T. Jr. | Tax withheld | 2.8K | $5.84 |
| 2026-02-27 | Falcione Aaron | Grant | 24K | — |
| 2026-02-27 | Falcione Aaron | Tax withheld | 8.7K | $7.17 |
| 2026-02-27 | Falcione Aaron | Grant | 6.7K | — |
| 2026-02-27 | Falcione Aaron | Tax withheld | 2.3K | $7.23 |
| 2026-02-27 | WALSH MATTHEW M | Grant | 43K | — |
| 2026-02-27 | WALSH MATTHEW M | Tax withheld | 15K | $7.17 |
| 2026-02-27 | WALSH MATTHEW M | Grant | 12K | — |
| 2026-02-27 | WALSH MATTHEW M | Tax withheld | 4.1K | $7.23 |
| 2026-02-27 | Nisita Vittorio | Grant | 16K | — |
| 2026-02-27 | Nisita Vittorio | Tax withheld | 6.2K | $7.17 |
| 2026-02-27 | Nisita Vittorio | Grant | 4.6K | — |
| 2026-02-27 | Nisita Vittorio | Tax withheld | 1.6K | $7.23 |
| 2026-02-27 | Stahler Rachel A | Grant | 23K | — |
| 2026-02-27 | Stahler Rachel A | Tax withheld | 8.5K | $7.17 |
| 2026-02-27 | Stahler Rachel A | Grant | 6.5K | — |
| 2026-02-27 | Stahler Rachel A | Tax withheld | 2.2K | $7.23 |
| 2026-02-27 | Weaver Kirke | Grant | 22K | — |
| 2026-02-27 | Weaver Kirke | Tax withheld | 6.8K | $7.17 |
| 2026-02-27 | Weaver Kirke | Grant | 6.2K | — |
| 2026-02-27 | Weaver Kirke | Tax withheld | 1.8K | $7.23 |
| 2026-02-27 | Morrissey Joseph T. Jr. | Grant | 28K | — |
| 2026-02-27 | Morrissey Joseph T. Jr. | Tax withheld | 8.1K | $7.17 |
| 2026-02-27 | Morrissey Joseph T. Jr. | Grant | 7.8K | — |
| 2026-02-27 | Morrissey Joseph T. Jr. | Tax withheld | 2.2K | $7.23 |
| 2025-11-12 | COX CARRIE SMITH | Buy | 65K | $7.67 |
| 2025-11-07 | Drinane Juliana Papa | Option exercise | 3.6K | — |
| 2025-11-07 | Drinane Juliana Papa | Tax withheld | 1.2K | $6.71 |
| 2025-11-07 | Arjona Ferreira Juan Camilo | Option exercise | 6.4K | — |
| 2025-11-07 | Arjona Ferreira Juan Camilo | Tax withheld | 2.3K | $6.71 |
| 2025-11-07 | Holzbaur Lynette | Option exercise | 2.4K | — |
| 2025-11-07 | Drinane Juliana Papa | Tax withheld | 1.2K | $6.71 |
| 2025-11-07 | Holzbaur Lynette | Tax withheld | 689 | $6.71 |
| 2025-11-05 | Holzbaur Lynette | Option exercise | 3.0K | — |
| 2025-11-05 | Holzbaur Lynette | Tax withheld | 866 | $6.52 |
| 2025-08-11 | Arjona Ferreira Juan Camilo | Option exercise | 12K | — |
| 2025-08-11 | Arjona Ferreira Juan Camilo | Tax withheld | 4.1K | $9.22 |
| 2025-05-14 | COX CARRIE SMITH | Buy | 12K | $8.07 |
| 2025-05-07 | Falcione Aaron | Buy | 5.5K | $8.77 |
| 2025-05-06 | Karp Daniel | Buy | 3.5K | $8.24 |
| 2025-05-06 | Weaver Kirke | Buy | 8.0K | $9.21 |
| 2025-05-05 | Ali Kevin | Buy | 34K | $8.80 |
| 2025-05-05 | WALSH MATTHEW M | Buy | 11K | $8.82 |
| 2025-03-31 | Nisita Vittorio | Tax withheld | 2.0K | $14.51 |
| 2025-03-31 | Nisita Vittorio | Option exercise | 4.6K | — |
| 2025-03-31 | Nisita Vittorio | Tax withheld | 1.6K | $14.51 |
| 2025-03-31 | Nisita Vittorio | Option exercise | 2.9K | — |
| 2025-03-31 | Nisita Vittorio | Tax withheld | 981 | $14.51 |
| 2025-03-31 | Morrissey Joseph T. Jr. | Option exercise | 9.8K | — |
| 2025-03-31 | Morrissey Joseph T. Jr. | Tax withheld | 4.2K | $14.51 |
| 2025-03-31 | Morrissey Joseph T. Jr. | Tax withheld | 3.4K | $14.51 |
| 2025-03-31 | Morrissey Joseph T. Jr. | Option exercise | 3.9K | — |
| 2025-03-31 | Morrissey Joseph T. Jr. | Tax withheld | 1.7K | $14.51 |
| 2025-03-31 | Ali Kevin | Option exercise | 49K | — |
| 2025-03-31 | Ali Kevin | Tax withheld | 27K | $14.51 |
| 2025-03-31 | Ali Kevin | Option exercise | 39K | — |
| 2025-03-31 | Ali Kevin | Tax withheld | 22K | $14.51 |
| 2025-03-31 | Ali Kevin | Option exercise | 21K | — |
| 2025-03-31 | Ali Kevin | Tax withheld | 12K | $14.51 |
| 2025-03-31 | Falcione Aaron | Option exercise | 8.4K | — |
| 2025-03-31 | Morrissey Joseph T. Jr. | Option exercise | 7.8K | — |
| 2025-03-31 | DiMarco Kathryn | Option exercise | 11K | — |
| 2025-03-31 | DiMarco Kathryn | Tax withheld | 3.6K | $14.51 |
| 2025-03-31 | DiMarco Kathryn | Option exercise | 8.5K | — |
| 2025-03-31 | DiMarco Kathryn | Tax withheld | 2.9K | $14.51 |
| 2025-03-31 | DiMarco Kathryn | Option exercise | 4.3K | — |
| 2025-03-31 | DiMarco Kathryn | Tax withheld | 1.5K | $14.51 |
| 2025-03-31 | Nisita Vittorio | Option exercise | 5.8K | — |
| 2025-03-31 | Karp Daniel | Tax withheld | 1.5K | $14.51 |
| 2025-03-31 | Karp Daniel | Option exercise | 4.3K | — |
| 2025-03-31 | Karp Daniel | Tax withheld | 1.3K | $14.51 |
| 2025-03-31 | Stahler Rachel A | Option exercise | 8.2K | — |
| 2025-03-31 | Stahler Rachel A | Tax withheld | 2.8K | $14.51 |
| 2025-03-31 | Stahler Rachel A | Option exercise | 6.6K | — |
| 2025-03-31 | Stahler Rachel A | Tax withheld | 2.6K | $14.51 |
| 2025-03-31 | Stahler Rachel A | Option exercise | 3.6K | — |
| 2025-03-31 | Stahler Rachel A | Tax withheld | 1.8K | $14.51 |
| 2025-03-31 | WALSH MATTHEW M | Option exercise | 15K | — |
| 2025-03-31 | WALSH MATTHEW M | Tax withheld | 7.4K | $14.51 |
| 2025-03-31 | WALSH MATTHEW M | Option exercise | 12K | — |
| 2025-03-31 | WALSH MATTHEW M | Tax withheld | 5.9K | $14.51 |
| 2025-03-31 | WALSH MATTHEW M | Option exercise | 7.8K | — |
| 2025-03-31 | WALSH MATTHEW M | Tax withheld | 3.8K | $14.51 |
| 2025-03-31 | Arjona Ferreira Juan Camilo | Option exercise | 8.9K | — |
| 2025-03-31 | Arjona Ferreira Juan Camilo | Tax withheld | 3.2K | $14.51 |
| 2025-03-31 | Weaver Kirke | Option exercise | 7.8K | — |
| 2025-03-31 | Weaver Kirke | Tax withheld | 2.2K | $14.51 |
| 2025-03-31 | Weaver Kirke | Option exercise | 6.2K | — |
| 2025-03-31 | Weaver Kirke | Tax withheld | 1.8K | $14.51 |
| 2025-03-31 | Weaver Kirke | Option exercise | 3.1K | — |
| 2025-03-31 | Weaver Kirke | Tax withheld | 891 | $14.51 |
| 2025-03-31 | Weaver Kirke | Option exercise | 4.3K | — |
| 2025-03-31 | Weaver Kirke | Tax withheld | 1.2K | $14.51 |
| 2025-03-31 | Falcione Aaron | Option exercise | 6.7K | — |
| 2025-03-31 | Falcione Aaron | Tax withheld | 2.6K | $14.51 |
| 2025-03-31 | Falcione Aaron | Option exercise | 3.6K | — |
| 2025-03-31 | Falcione Aaron | Tax withheld | 1.8K | $14.51 |
| 2025-03-31 | Karp Daniel | Option exercise | 14K | — |
| 2025-03-31 | Karp Daniel | Tax withheld | 4.4K | $14.51 |
| 2025-03-31 | Karp Daniel | Option exercise | 11K | — |
| 2025-03-31 | Karp Daniel | Tax withheld | 3.6K | $14.51 |
| 2025-03-31 | Karp Daniel | Option exercise | 4.9K | — |
| 2025-03-29 | Falcione Aaron | Tax withheld | 2.9K | $14.51 |
| 2025-02-20 | Ali Kevin | Grant | 15K | — |
| 2025-02-20 | Ali Kevin | Tax withheld | 8.5K | $15.29 |
| 2025-02-20 | WALSH MATTHEW M | Grant | 30K | — |
| 2025-02-20 | WALSH MATTHEW M | Tax withheld | 11K | $14.92 |
| 2025-02-20 | WALSH MATTHEW M | Grant | 5.6K | — |
| 2025-02-20 | WALSH MATTHEW M | Tax withheld | 1.9K | $15.29 |
| 2025-02-20 | Stahler Rachel A | Grant | 14K | — |
| 2025-02-20 | Stahler Rachel A | Tax withheld | 5.1K | $14.92 |
| 2025-02-20 | Stahler Rachel A | Grant | 2.6K | — |
| 2025-02-20 | Stahler Rachel A | Tax withheld | 881 | $15.29 |
| 2025-02-20 | Nisita Vittorio | Grant | 11K | — |
| 2025-02-20 | Nisita Vittorio | Tax withheld | 4.2K | $14.92 |
| 2025-02-20 | Nisita Vittorio | Grant | 2.1K | — |
| 2025-02-20 | Nisita Vittorio | Tax withheld | 705 | $15.29 |
| 2025-02-20 | Morrissey Joseph T. Jr. | Grant | 15K | — |
| 2025-02-20 | Morrissey Joseph T. Jr. | Tax withheld | 4.7K | $14.92 |
| 2025-02-20 | Morrissey Joseph T. Jr. | Grant | 2.8K | — |
| 2025-02-20 | Morrissey Joseph T. Jr. | Tax withheld | 806 | $15.29 |
| 2025-02-20 | Falcione Aaron | Grant | 14K | — |
| 2025-02-20 | Falcione Aaron | Tax withheld | 5.2K | $14.92 |
| 2025-02-20 | Falcione Aaron | Grant | 2.6K | — |
| 2025-02-20 | Falcione Aaron | Tax withheld | 881 | $15.29 |
| 2025-02-20 | Ali Kevin | Grant | 84K | — |
| 2025-02-20 | Ali Kevin | Tax withheld | 47K | $14.92 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07265479 ↗ | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Atopic Dermatitis | PHASE3 | Recruiting | 2028-01-01 |
| NCT05172726 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects Plaque Psoriasis | PHASE3 | Active Not Recruiting | 2026-10-01 |
| NCT05560646 ↗ | A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain Endometriosis | PHASE2 | Completed | 2025-05-28 |
| NCT04626596 ↗ | A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) Contraception | PHASE3 | Completed | 2024-12-30 |
| NCT05761444 ↗ | Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients Atherosclerotic Cardiovascular Disease | PHASE4 | Completed | 2024-09-04 |
| NCT05142774 ↗ | Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis Atopic Dermatitis | PHASE3 | Completed | 2024-02-29 |
| NCT05264506 ↗ | Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive Contraception | PHASE3 | Terminated | 2024-01-12 |
| NCT05789576 ↗ | A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region Psoriasis | PHASE4 | Completed | 2023-06-30 |
| NCT05680740 ↗ | A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis Psoriasis | PHASE4 | Completed | 2023-05-18 |
| NCT05014568 ↗ | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults Atopic Dermatitis | PHASE3 | Completed | 2023-03-30 |
| NCT05032859 ↗ | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) Atopic Dermatitis | PHASE3 | Completed | 2023-02-03 |
| NCT05186805 ↗ | Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis Atopic Dermatitis | PHASE2 | Completed | 2022-08-24 |
| NCT04053387 ↗ | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) Plaque Psoriasis | PHASE3 | Completed | 2021-04-06 |
| NCT03768427 ↗ | Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439) Hypercholesterolemia | PHASE3 | Completed | 2021-03-17 |
| NCT03956355 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Plaque Psoriasis | PHASE3 | Completed | 2020-05-26 |
| NCT03983980 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Plaque Psoriasis | PHASE3 | Completed | 2020-05-13 |
| NCT03019575 ↗ | Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043) Hypogonadotropic Hypogonadism | PHASE3 | Completed | 2020-05-05 |
| NCT04042103 ↗ | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis Plaque Psoriasis | PHASE2 | Completed | 2020-01-09 |
| NCT01327638 ↗ | Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082) Spondylarthropathies; Spondylitis, Ankylosing | — | Completed | 2018-09-24 |
| NCT01498770 ↗ | An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) Bipolar Disorder | — | Completed | 2017-12-21 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (0)
Suppliers (1)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-11 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-04-30 | ResultsExhibits | filing ↗ |
| 2026-04-27 | Material agreementExec/director changeReg FDExhibits | filing ↗ |
| 2026-02-20 | OtherExhibits | filing ↗ |
| 2026-02-12 | ResultsReg FDExhibits | filing ↗ |
| 2025-11-10 | ResultsReg FDExhibits | filing ↗ |
| 2025-11-07 | Exec/director change | filing ↗ |
| 2025-10-30 | Exec/director changeExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-09 | 0001104659-26-072953 ↗ |
| 10-Q | 2026-05-04 | 2026-03-31 | 0001628280-26-029532 ↗ |
| 8-K | 2026-04-30 | 2026-04-30 | 0001104659-26-052165 ↗ |
| 8-K | 2026-04-27 | 2026-04-26 | 0001193125-26-178718 ↗ |
| 10-K | 2026-02-24 | 2025-12-31 | 0001628280-26-011125 ↗ |
| 8-K | 2026-02-20 | 2026-02-20 | 0001104659-26-017870 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001104659-26-013888 ↗ |
| 10-K/A | 2025-11-10 | 2024-12-31 | 0001104659-25-108693 ↗ |
| 10-Q/A | 2025-11-10 | 2025-03-31 | 0001104659-25-108732 ↗ |
| 10-Q/A | 2025-11-10 | 2025-06-30 | 0001104659-25-108740 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001104659-25-108821 ↗ |
| 10-Q | 2025-11-10 | 2025-09-30 | 0001628280-25-050795 ↗ |